Molbio Diagnostics Raises Rs 281.5 Cr From Anchor Investors

Molbio Diagnostics has collected Rs 281.5 crore from anchor investors ahead of its initial public offering, which aims to raise between Rs 904 crore and Rs 940 crore. The company plans to use the funds for infrastructure improvements, new equipment, and general corporate purposes.

The IPO price band is fixed at Rs 768-807 per share, with the company allotting 34.88 lakh shares to 33 anchor investors at Rs 807 per share. The IPO will open for public subscription on August 10 and close on August 12, with the company's shares set to make their debut on August 17.

The IPO comprises a fresh issue of shares worth Rs 200 crore and an offer for sale (OFS) of Rs 739.70 crore. The company will utilize Rs 106 crore towards capital expenditure for setting up infrastructure for an R&D facility, Centre of Excellence and connected office space. Additionally, Rs 80.81 crore will be allocated towards purchasing plant, machinery, and other equipment for its manufacturing facilities located in Goa and Visakhapatnam.

## What happens next The company's shares are expected to list on August 17, following the completion of the IPO. Several brokerages have given the issue a Subscribe rating, citing the company's healthy financial performance between FY24 and FY26.

## Why it matters The investment by anchor investors marks a notable institutional endorsement for Molbio Diagnostics, which is regarded as Goa's first unicorn and is backed by Temasek and Motilal Oswal Private Equity. The pre-IPO secondary deal points to strong institutional interest in Molbio ahead of its listing. The company's plans to use the funds for infrastructure improvements and new equipment are expected to support its growth plans.

The IPO has received positive recommendations from several brokerages, including BP Wealth, Swastika Investmart, and Ventura Securities, which have given the issue a Subscribe rating. SBI Securities has recommended Subscribe for Long Term, citing the company's healthy financial performance.